Two multicenter, open-label, nonrandomized dose-escalation studies were conducted in which the administration of esaxerenone as a monotherapy and as an add-on to renin-angiotensin system inhibitor therapy was compared in Japanese patients with hypertension and moderate kidney dysfunction. Here, REN is linked to hypertensive disorder.